IMMUNEONCO-B (01541) shares surged over 14% in early trading, and as of the time of writing, were up 10.78% to HK$3.495, with a turnover of HK$3.1368 million.

On the news front, IMMUNEONCO-B announced that its subsidiary, ImmuneCore, entered into a capital increase agreement with Shengke Qihang, Xinjie Chuangyuan, and Wang Xueyan. The three investors collectively subscribed for a total of 465,000 yuan of ImmuneCore's expanded registered capital, representing approximately 15.83% of its enlarged equity, for a total consideration of RMB 50 million.

This capital increase is intended to further strengthen ImmuneCore's financial resources, accelerating its innovative drug development in cardiovascular diseases such as pulmonary hypertension and metabolic disease areas. It marks the steady implementation of IMMUNEONCO-B's "oncology plus non-oncology" dual-engine strategy.

By introducing external commercial capital for the first time, ImmuneCore has successfully transitioned to a diversified equity structure, aiming to expedite its innovative drug research and development in cardiovascular diseases like pulmonary hypertension and metabolic disorders.